Provectus Biopharmaceuticals, Inc.
http://www.provectusbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Provectus Biopharmaceuticals, Inc.
Amylyx Steps Outside Neurodegenerative Disease With New Late-Stage Asset
The company outlined plans to develop newly acquired GLP-1 antagonist avexitide. CEOs Joshua Cohen and Justin Klee talked to Scrip about the strategy.
AnGes To Withdraw, Refile HGF Gene Therapy In Japan
If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.
AnGes To Withdraw, Refile HGF Gene Therapy In Japan
If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Medical Devices
- Laser
- Other Names / Subsidiaries
-
- Provectus Biopharmaceuticals Australia Pty Ltd.
- Provectus Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice